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Abstract Extracellular vesicles (EVs)—particularly exosomes and microvesicles (MVs)—are attracting considerable interest in
the cardiovascular field as the wide range of their functions is recognized. These capabilities include transporting
regulatory molecules including different RNA species, lipids, and proteins through the extracellular space including
blood and delivering these cargos to recipient cells to modify cellular activity. EVs powerfully stimulate angiogenesis,
and can protect the heart against myocardial infarction. They also appear to mediate some of the paracrine effects
of cells, and have therefore been proposed as a potential alternative to cell-based regenerative therapies.
Moreover, EVs of different sources may be useful biomarkers of cardiovascular disease identities. However, the
methods used for the detection and isolation of EVs have several limitations and vary widely between studies, lead-
ing to uncertainties regarding the exact population of EVs studied and how to interpret the data. The number of
publications in the exosome and MV field has been increasing exponentially in recent years and, therefore, in this
ESC Working Group Position Paper, the overall objective is to provide a set of recommendations for the analysis
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and translational application of EVs focussing on the diagnosis and therapy of the ischaemic heart. This should help
to ensure that the data from emerging studies are robust and repeatable, and optimize the pathway towards the
diagnostic and therapeutic use of EVs in clinical studies for patient benefit.
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1. Introduction
1.1 Cellular secretion for communication;
extracellular vesicles
Cells in multicellular organisms must communicate efficiently with each
other in order to propagate signals and co-ordinate function. In addition
to distinct chemical signals (paracrine and endocrine) and direct cell-cell
contact, a growing body of evidence shows that cells communicate via a
variety of small, membrane-enclosed vesicles, collectively termed
‘extracellular vesicles’ (EVs). EVs ranging from 40 nm to several
microns in size (Figure 1), are released into all extracellular fluids includ-
ing blood. They transport a cell-specific cargo of proteins, lipids, metabo-
lites, and nucleic acids that can affect target cells. This process occurs
during normal cellular physiology as well as during stress and disease. In
this rapidly evolving area of research, with its associated technical chal-
lenges, it is vital to establish standardized techniques for their isolation
and criteria for their identification. EVs are released by all cardiac, endo-
thelial and inflammatory cell types, suggesting they have an important
role in the cardiovascular system, including the ischaemic heart.1–6
Therefore, the overall objective of this position paper is to provide a
set of recommendations for the isolation, characterization, analysis, and
translational application of EVs focussing mainly on the ischaemic heart,
i.e. acute myocardial infarction and post-ischaemic heart failure.
Coronary atherosclerosis is not discussed in this position paper in detail
(see recent reviews and position papers of the European Society of
Cardiology that covers this topic extensively7–9).
2. Isolation and characterization of
EVs
2.1 Definition of EVs
Eukaryotic EVs include (i) exosomes released by exocytosis of multivesicu-
lar bodies (usually 50–150 nm), (ii) Microvesicles (MVs, also called micro-
particles or ectosomes), vesicles around 0.1–1lm in diameter shed from
the plasma membrane,10–12 and (iii) apoptotic vesicles released by blebbing
of apoptotic cells some of which are > 1lm (apoptotic bodies),13,14 and
(iv) large oncosomes released by migratory tumour cells (> 1mm)15,16
(Figure 2). However, since current isolation protocols only result in relative
enrichment of vesicle subpopulations rather than their complete
purification,17 and that no specific markers are available for the subpopula-
tions, it is preferable to refer to purified vesicles as ‘EVs’ and accurately
report the purification method used and characteristics present. An opera-
tional definition of small EVs (sEVs) is appropriate for the exosome-
enriched population pelleting at high speeds.17
2.2 Methods for the isolation and
characterization of EVs
Several methods of isolating EVs have been developed (Figure 3). The
optimal EV isolation procedure will depend on the source biofluid, the
EV subpopulation of interest, and their intended end-use, whether that is
to be diagnostic biomarker studies, mechanistic studies, or for in vivo
administration. However, no EV isolation method yet exists that can be
considered as a gold standard, since residual proteins and/or lipoproteins
remains problematic.18 Complete removal of lipoproteins (present in
both blood and tissue culture serum) remains challenging due to over-
lapping size and/or densities between EVs and different lipoprotein par-
ticles (Figures 1 and 2).12,19,20 Moreover, low density lipoprotein (LDL)
and exosomes may associate, rendering their complete separation from
blood samples impossible using any technique.12 This, however, might be
used in isolating a subset of EVs co-precipitated with LDL or high density
lipoprotein (HDL) particles.21,22
In the simplest technique based on precipitation (e.g. ExoQuickTM),
the biofluid sample is mixed and incubated with a hydrophilic polymer
prior to low speed centrifugation. The polymers attract water molecules
away from the solvation layer around the EVs causing their precipitation.
Several manufacturers now market products based on this technique.
However, they result in high levels of contaminants including serum pro-
teins and lipoproteins as well as residual matrix that can affect EV biologi-
cal functions.23,24
Differential centrifugation has long been regarded as the gold standard
technique.19 In the most commonly used protocol, cells are removed by
centrifugation at 300 x g for 10 min; the supernatant is then cleared of
apoptotic bodies by centrifugation at 2000 x g for 10 min followed by
10 000 x g for 30 min to preferentially pellet MVs; exosome-enriched
sEVs are then purified from the supernatant by ultracentrifugation at
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Figure 1 Exosomes and MVs overlap in size with VLDL and chylomi-
crons, and in density with HDL/LDL particles. Exosome density is typi-
cally 1.06–1.20 g/mL. MV density is not well defined but they have been
found between1.03–1.08 g/mL.10–12
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
20 J.P.G. Sluijter et al.
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
100 000 x g for 70 min.19 However, optimal parameters are highly
dependent on the type of centrifuge rotor used.25 For further purifica-
tion of EVs from co-pelleted protein complexes26 and lipoproteins, a
density gradient is recommended (sucrose or preferably iodixanol).19
Because of the number of steps involved and the length of the proce-
dure, it is clearly unsuited for the analysis of large numbers of samples.
More recently, concerns have been raised that ultracentrifugation can
cause damage, fusion, and/or aggregation of vesicles.27
There is increasing enthusiasm for the use of size-exclusion
chromatography.28 Suitable matrices include Sepharose 2B, Sepharose
CL-4B, or Sephacryl S-400.29 The resolution of size separation is
dependent on column length. This technique is effective at separating
EVs from proteins and some lipoproteins, but samples usually become
considerably diluted and efficient separation of lipoproteins remain
challenging.12,29,30
Other techniques are less well established. Filtration (0.2 lm–
0.8 lm) aids in removal of larger vesicles, but under high pressure it is
possible that it could cause the fragmentation of larger EVs into
smaller vesicles. Immuno-affinity can be an effective means to isolate
specific EV populations, using columns or magnetic beads for exam-
ple, but for functional follow-up studies this is still challenging. Flow
cytometry-based analysis of individual EVs is a valuable tool for EV
characterization and quantification, although it remains challenging
due to size and sensitivity limitations.31 Progress has been made in
developing these technologies for specific EV sorting, but some pre-
requisite steps need to be taken.32 Furthermore, this approach
requires certainty as to the specificity of epitopes expressed by the
desired population of EVs–which may not be the case for exo-
somes.33 Other isolation techniques such as microfluidics are under
development but have not yet been rigorously tested. For pre-clinical
or clinical studies of the ischaemic heart, measurement of EVs can be
performed from in vivo blood, lymphatic or pericardial fluid samples,
ex vivo heart perfusate samples, and tissue culture media samples that
may require different isolation techniques.
2.2.1 Isolation from blood
Pre-analytical procedures can have a large impact on blood EV measure-
ments. For example, since clotting may increase the number of EVs in
blood by 10-fold,34 it is usually preferable to use plasma. On the other
hand, serum may be useful when overall yield of platelet MVs is more
important than accurate quantification of particle number. A crucial con-
cern is the minimization of platelet activation and EV release.
Standardized procedures to minimize platelet activation during plasma
isolation should be followed.35,36 Fasting before blood sampling can help
to minimize chylomicron contamination.12 Blood should be collected in
citrated or acid-citrate-dextrose anticoagulant tubes,23,35,37 such as vacu-
tainers, and the first tube of blood should be discarded.23,35 It is recom-
mended to dilute blood plasma or serum at least 2x in Ca2þ-free
phosphate buffered saline (PBS) prior to centrifugation in order to
reduce the viscosity.19 However, if annexin V binding will be assessed
(which requires Ca2þ), PBS should be avoided in order to prevent for-
mation of calcium-phosphate micro-precipitates. The plasma or serum
should be centrifuged within 2 h, and agitation avoided.35,38 After centri-
fugation at 2500 x g for 15 min at room temperature without application
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Figure 2 The major classes of EV. Typical size and density of EV classes and some of the contaminants that may be co-isolated, depending on biofluid.
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Figure 3 Standard techniques used for isolating exosomes from
other EVs, protein, and lipoproteins present in blood and cell-culture
medium.
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of the centrifuge brake, plasma can be carefully collected, and re-
centrifuged under identical conditions. This platelet-free-plasma may be
snap frozen and stored at –80 C prior to analysis.
Even when using the same protocol, inter-laboratory variability in
plasma EV counts can vary by an order of magnitude.35 Given these
problems of irreproducibility, The International Society on Thrombosis,
and Haemostasis has advised that further refinements are required
before flow cytometric enumeration of platelet MV numbers is ready for
clinical use.35
2.2.2 Isolation from pericardial fluid
Pericardial fluid contains EVs that may provide useful biomarker informa-
tion about cardiac health.39,40 As yet there is no consensus as to the ideal
method for isolation of EVs from pericardial fluid.
2.2.3 Isolation from conditioned media of cultured cells
For the isolation of vesicles produced by cells in tissue culture the impor-
tant considerations are quite different. The main potential source of con-
tamination is typically from foetal calf serum (FCS) added to the culture
medium.41 FCS contains large number of vesicles including exosomes as
well as lipoproteins. Exosomes can be largely removed by pre-treating
FCS by 18 h ultracentrifugation at 100 000 g,41 and removal is
enhanced by diluting FCS five-fold in culture medium to reduce viscos-
ity.23 Several companies market FCS which has been processed to
remove exosomes, though the method used is not specified. However,
some caution should be taken for FBS-associated RNA which might be
co-isolated with cell-culture derived extracellular RNA (exRNA),
thereby interfering with the downstream RNA analysis.42 Alternatively,
pre-defined serum or serum-free conditions can be used, and indeed is
essential if preparing EVs for clinical use.43 However, cells may undergo
apoptosis or autophagy and release apoptotic bodies after extended
periods in the absence of serum. Conditioned medium is usually col-
lected after 24–48 h culture. Although sequential filtration offers the
advantage of using large volumes of culture media,44 its effect on biologi-
cal activity of the isolated EVs has not been well characterized. HPLC has
been successfully used to purify exosomes.45
2.2.4 Isolation from isolated heart perfusate
EVs can be isolated from hearts perfused with buffer such as those
mounted on a Langendorff apparatus.46 Pre-concentration of the perfu-
sate by ultrafiltration may be necessary for a sufficient yield, but subse-
quently any of the techniques described above may be used. It is
important to be aware that exosome-sized, calcium-phosphate nanopar-
ticles form spontaneously in Ca2þ-containing bicarbonate buffer, which
can interfere with some analyses such as nanoparticle tracking analysis.47
2.2.5 Storage of EVs
EVs appear to be relatively stable when stored at –80 C or less,48 but
repeated freeze-thaw cycles should be avoided and cryo-preservatives
such as glycerol and DMSO should not be added as they may lyse EVs.48
Trehalose has recently been proposed to preserve exosomes.49
2.2.6 Visualization and quantitation of EVs
In most studies, it is informative to quantify EVs using either nanoparticle
tracking analysis, tuneable resistive pulse sensing, or dynamic light scat-
tering (Figure 4). Importantly, these methods usually do not discriminate
EVs from non-vesicular events such as LDL particles.12 The ratio of par-
ticle number or lipid content to protein content of the preparations can
give an indication of relative EV purity, as compared to protein concen-
tration only.50,51 Exosome morphology should be confirmed by trans-
mission electron microscopy,19 cryo-electron microscopy,52 or atomic
force microscopy.53 In addition, presented images should contain multi-
ple EVs per field (Figure 4A). Using flow cytometry, the lower size-limit of
detection is steadily decreasing, but it remains technically challenging to
obtain comprehensive analyses of MVs let alone exosome-sized
particles.32
2.2.7 Characterization of EVs
Further characterization of EVs should include the detection of specific
markers. It is generally recommended to demonstrate presence of tetra-
spanin proteins such as CD9, CD81, CD63, and the intra-vesicular pro-
tein Alix, which are involved in exosome biogenesis, in addition to other
typical marker proteins such as HSP70, flotillin-1, or major histocompati-
bility complex (MHC) class I and class II. However, recent studies indi-
cate some of these are not as specific for exosomes as thought.17,54
Co-enrichment of CD63, CD9, and CD81 tetraspanins and endosome
markers such as syntenin-1 and TSG101 may be seen as indicative of
exosome presence.17 MV surface marker expression is a useful index of
cell-type of origin, and can be quantified by flow cytometry in order to
analyse sub-populations. In addition, MVs may be characterized as
‘calcium-dependent annexin V binding’ or ‘calcium-independent lactad-
herin (MFGE8) binding’. Gating strategies for flow cytometry involve the
use of fluorescent reference beads of known sizes. Preferred beads are
the silica beads because their refractive index is close to the one of bio-
logical particles.55 Of note, not all MVs are detectable this way. To quan-
titatively detect exosome proteins, a nano-plasmonic exosome sensor
was developed that comprises arrays of periodic nanoholes patterned in
a metal film. The arrays are functionalized with affinity ligands for differ-
ent exosomal protein markers and offers highly sensitive and label-free
exosome analyses by continuous and real-time monitoring of molecular
binding.56
In order to demonstrate EV functionality it may be useful to demon-
strate their interaction with, fusion, or uptake into recipient cells. To this
end, EVs can be fluorescently labelled with lipophilic dyes, or by transfec-
tion of parent cells with GFP-tagged proteins packaged in EVs. Control
experiments using ‘dye-only’ samples prepared in parallel the same way
as EVs are essential to confirm the involvement of EVs57 and that free
dye has been removed, which can otherwise form micelles. Density gra-
dient ultracentrifugation is a frequently used approach to remove this
non-EV-associated dye. Co-incubation with receptor antagonists or
uptake inhibitors will provide insights in mechanisms of uptake although
these compounds are notorious for their toxicity and limited
specificity.58
2.2.8 Analysis of nucleic acid, protein, and lipid contents
of EVs
Proteomics can provide a more comprehensive description of EV pro-
tein content, but the isolation protocol must be carefully optimized in
order to remove plasma protein contamination in blood EV samples.59,60
Similar concerns arise with transcriptomic analyses of miRNA, mRNA,
or DNA contents, particularly with regard to potentially contaminating
HDL particles and argonaute 2-RNA complexes, which are known to
transport miRNA.61 Care must be taken to avoid haemolysis which can
affect circulating miRNA levels.62
EV proteomics has been studies in large clinical cohorts,63 but
undoubtedly the greatest interest is currently focused at the RNA
22 J.P.G. Sluijter et al.
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content of EVs as potential biomarkers.63EV lipidomics is an interesting
but under-explored area.64 Nucleic acid, protein and lipid entries from
EV studies are available in EV databases (http://www.exocarta.org/,
http://student4.postech.ac.kr/evpedia2_xe/xe/ and http://microvesicles.
org/ (10 November 2017, date last accessed)). However, because of the
diversity of EV isolation protocols used, these database entries should be
treated with caution.
2.2.9 Technical control experiments
RNase or protease may be applied to remove extra-vesicular nucleic
acids and proteins and confirm intra-vesicular localization. Detergent
control during flow cytometry or sizing performed by tuneable resistive
pulse sensing or dynamic light scattering enables distinguishing EVs from
protein aggregates (the latter being more resistant to detergents lysis
than EVs).26,65,66 Of note, small and large EVs have different detergent
sensitivities67 and lipoproteins also show a limited sensitivity to deter-
gent lysis.12
2.3 Recommendations for isolation and
purification of EVs
At present, there is no universally agreed protocol for isolation of pure
populations of EVs or subpopulations of EVs. Even their precise nomen-
clature is in flux, and will presumably remain so until clear surface protein
signatures of individual EV subtypes will be established. Given the rapid
A spoer’s guide to EVs under Transmission Electron Microscopy
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Figure 4 Standard methods of characterizing EVs. (A) Transmission electron microscopy (TEM) of negative-stained EVs reveals the ‘cup-shaped’ appear-
ance of exosomes (E) and MVs once they have been dried for TEM (they are spherical in solution). (B) The spherical appearance of lipoprotein particles by
TEM is quite distinct (image courtesy of Robert L. Hamilton and the Arteriosclerosis Specialized Center of Research, University of California, San Francisco).
(C) Nanoparticle tracking analysis (NTA) provides a size distribution of particles based on calculating their size by their random Brownian motion. (D, E)
Tuneable resistance pulse sensing (TRP) determines size distribution by the change in resistance as the particle crosses a small pore in a membrane (which is
selected according to the size range examined).
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.developments in this area it is important to remain cognizant of experi-
mental limitations and caveats in order to avoid overstating conclusions.
At present, it is challenging to isolate EVs from tissue homogenates. The
likely contamination of EV preparations with proteins and lipoproteins
renders many results suspect unless crucial control experiments are per-
formed. Differential detergent lysis is a simple, inexpensive EV control
for flow cytometry.26,65 Furthermore, to avoid swarm detection at high
particle concentrations, analysis of serial dilution of samples is recom-
mended during flow cytometry.32 A characterization of EV proteins
will provide a basis on purity without excluding a potential biological
role. Table 1 provides a check-list of criteria for the successful isolation
and characterization of EVs, as well as more specific criteria for
exosomes.
3. Mechanism of EV actions in the
heart
EVs appear to be released from all major cell types found in the heart.
For example, exosomes have been shown to be released by primary
adult cardiomyocytes,68,69 primary cardiac endothelial cells,70 primary
cardiac fibroblasts,71 and vascular smooth muscle cells.72 Most MVs
present in the plasma of healthy individuals are derived from platelets
and erythrocytes, but plasma MVs also originate from leucocytes, endo-
thelial cells, monocytes neutrophils, and lymphocytes.73,74 Most mecha-
nistic experiments to date use EVs isolated from cultured cells, since
isolation of cell-type specific EVs in vivo is not currently feasible. Recently,
a clear overview was provided on the role of EVs in coronary artery dis-
ease.7 This section will discuss the most relevant examples of the func-
tion of EVs released from cells of the heart tissue and their postulated
mechanisms of action.
3.1 Cardiomyocyte-derived EVs
Cardiomyocytes are potentially an important source of diagnostic EVs
particularly in situations of stress such as myocardial ischaemia and fail-
ure.1 However, few studies have examined exosomes from adult as
opposed to neonatal cardiomyocytes, and even here it is unclear to
what extent this relates to the situation in vivo. In vitro, hypoxia and re-
oxygenation leads to the release of heat shock proteins (HSPs) HSP70
and HSP90, as well as HSP60, a ‘danger signal’, via exosomes in primary
adult rat cardiomyocytes.68 Cardiomyocytes also release EVs containing
tumour necrosis factor (TNF)-a,75 potentially participating in the propa-
gation of an inflammatory response. Glucose deprivation induced the
loading of neonatal rat cardiomyocyte exosomes with functional glucose
transporters and glycolytic enzymes. When internalized by endothelial
cells, these exosomes increased glucose uptake, glycolytic activity, and
pyruvate production in recipient cells.76 The transfer of exosomes from
glucose-deprived H9C2 cardiac myoblasts to endothelial cells also
induced changes in transcriptional activity of pro-angiogenic genes.77
Hyperglycaemia altered cardiomyocyte-derived exosomes in a model of
diabetes-associated cardiomyopathy,78 as well as from the hypoxic myo-
cardium which can activate in vitro cultured endothelial cells.79,80 Finally,
external stretch caused cardiomyocytes to release exosomes enriched
Table 1 Recommendations for the isolation and characterization of EVs [adapted from Ref. 18]
General recommendations for EVs
(1) EVs can be isolated from either tissue culture supernatant or extracellular fluids. Reliable methods for EV isolation from tissue homogenates remain to be
established.
(2) Ensure consistency of pre-analytical procedures.
(3) Report complete experimental details, including pre-analytical and isolation procedure and details of all antibodies used.190 Also include all negative data
sets.
(4) If EV function is analysed, include:
a. a dose-response curve.
b. systematic negative (‘EV-depleted’) controls.
c. demonstrate an association between a protein/miRNA and EVs in support of any function ascribed to them, e.g. using immuno-EM, or co-purification on
a density gradient.
Specific recommendations for exosomes
(1) Avoid precipitation methods of isolation,
(2) Tissue culture of cells for exosome isolation must be cultured with exosome-free FCS or under FCS-free conditions,
(3) Confirm the presence of at least 3 ‘marker’ proteins typically enriched in exosomes, e.g.
a. Tetraspanins: CD9, CD63a, and CD81
b. Endosomal markers: Syntenin-1 and TSG101
(4) Assess levels of contaminating proteins, e.g. serum albumin, extracellular matrix, mitochondrial, nuclear protein, argonaute, lipoproteins. It is not currently
possible to state a ‘minimum acceptable level’ but protein contamination can form an important internal quality control.
(5) If electron microscope images are shown, they should include more than 1 exosome per field.
(6) Determine the size distribution using two orthogonal techniques, e.g.: nanoparticle tracking analysis, electron microscopy, tuneable resistive pulse sensing or
dynamic light scattering.
Specific recommendations for MVs
(1) Establish rigorous guidelines for consistency of isolation methods,
(2) Determine the accuracy and precision (coefficient of variation) of the quantification methods used.
aSome markers such as CD63 may not be completely specific for exosomes.17
24 J.P.G. Sluijter et al.
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in functional angiotensin II type-1 receptors (AT1Rs).69 Administration
of AT1R-enriched exosomes restored responsiveness to angiotensin II
in the vessels of AT1R-KO mice. Together, these data indicates that car-
diomyocytes respond to environmental changes by releasing specific EVs
that specifically modulate neighbour-cell function.
3.2 Cardiac progenitor cells-derived EVs
A variety of cells with the capacity to proliferate and differentiate into
cardiac cells have been termed cardiac progenitor cells (CPCs).
Exosomes released from these cell types appear to recapitulate the car-
dioprotective and regenerative benefits of their parent cells.81,82
Hypoxia stimulated exosome release from CPCs and upregulated their
expression of pro-angiogenic genes, anti-fibrotic genes, and a cluster of
miRs, and increased their ability to improved cardiac function after IR
injury in rats.83,84 Vrijsen et al. reported that human CPCs release exo-
somes into their environment, and that exosomes from CPCs are able
to stimulate the migration of endothelial cells in an in vitro scratch wound
assay.85 They also showed that CPC-exosomes contain matrix metallo-
proteinases (MMPs) and the extracellular matrix metalloproteinase
inducer (EMPRINN), which mediate their angiogenic potential.86
3.3 Endothelial cell-derived EVs
Endothelial cells are an important source of EVs. Vascular endothelial
cells secrete exosomes and MVs that exchange biological messages with
other cell types of the heart.4,7 There is extensive literature demonstrat-
ing the effects of endothelial MV in promoting angiogenesis (reviewed in
Ref. 87). Endothelial exosomes have also been shown to stimulate angio-
genesis via a mechanism that is believed to involve transfer of miR-
146a.88 Hypoxia alters mRNA and protein composition of exosomes
released by cultured endothelial cells.89 TNF-a-treated endothelial cells
release exosomes expressing increased levels of intercellular adhesion
protein (ICAM)-1.89 These findings exemplify the potential function of
endothelial cell-derived exosomes and MV that may also make them use-
ful as biomarkers of cardiac stress and disease.4,9
3.4 Vascular progenitor cell-derived EVs
While their exact differentiation potential has been debated, it is evident
that CD34þ cells from bone marrow secrete exosomes that possess
angiogenic characteristics, enhance tube formation of endothelial cells,
and increase neovascularization in vivo.90 Further analysis revealed
enrichment of several pro-angiogenic miRs (miR-126 and 130a) in
CD34þ cell-derived exosomes. MVs derived from human vascular pro-
genitor cells carry several markers similar to receptors expressed on
their membranes.91 In various disease models, these MVs were shown
to enhance expression of angiogenic miRs (miR-126 and 296), and pro-
mote neovascularization of pancreatic islets92 and ischaemic hind limb.93
3.5 EVs from fibroblasts, smooth muscle
cells, and mesenchymal stromal cells
Ischaemia, pressure, and volume overload induce hypertrophic cellular
responses mediated by cross-talk among fibroblast cardiomyocytes,
endothelial cells, and inflammatory cells via EVs. In response to angioten-
sin II, cardiac fibroblasts secreted exosomes that stimulated angiotensin
II production and its receptor expression in cardiomyocytes, and stimu-
lated myocyte hypertrophy.94 Exosomes released from cardiac fibro-
blasts contained high levels of miR-21-3p/miR-21, which induced
cardiomyocyte hypertrophy.94 Smooth muscle cells also release exo-
somes and are implicated in vessel calcification and atherosclerosis.72,95
Mesenchymal stromal/stem cells (MSCs) are resident in almost all tis-
sues, including the heart, and play a major role in tissue repair and regen-
eration.96 Characterization of the MSC exosome proteome has
revealed many cytokines, growth factors, inflammatory molecules, com-
ponents of the extracellular matrix, and proteases. Analysis of protein
content revealed >400 different proteins.97 Many signalling molecules
related to MSC self-renewal, differentiation, and signalling pathways
were found to be enriched in MSC exosomes, potentially affecting a
diverse range of cellular processes, including cell cycle, proliferation, cell
adhesion, cell migration, and cell morphogenesis. Similarly, miRNAs shut-
tle within MSC exosomes but mostly in precursor form, driving down-
stream signalling pathways. Additionally, MSC exosomes possess
immunologic properties, including secretion of anti-inflammatory cyto-
kines, such as interleukin-10, tumour growth factor (TGF)-b, and pro-
mote inhibition of lymphocyte proliferation.98
3.6 Immune cell-derived EVs
Immune system cells, such as B cells and dendritic cells, mediate MHC-
dependent immune responses upon EV secretion.99,100 For this purpose,
vesicles express particular adhesion molecules for specific targeting of
recipient cells.101 Other immune cells release MVs with immune func-
tions, for example, NK-derived exosomes enclose perforin and gran-
zyme B and mediate anti-tumour activities either in vitro or in vivo.102
Furthermore, peptides expressed in exosomes released by mast cells
are presented by DCs and induce specific immune responses in vivo.103 It
has also been reported that macrophages release IL-1b on inflamma-
some activation, suggesting that these MVs play a role in pro-
inflammatory activity and innate immune response.104
3.7 Platelet-derived EVs
Platelets release both exosomes and MVs,105 and release is strikingly
enhanced by many stimuli, including physicochemical stresses and apop-
tosis.106 Platelet-derived exosomes are able to regulate the coagulation
response,105 and mediate platelet atherogenic interactions with endo-
thelial cells and monocytes.107,108 Platelet MV stimulate angiogenesis and
intramyocardial injection improved post-ischaemic revascularization.109
Platelet exosomal cargoes include diverse cytokines, chemokines,
growth factors, coagulation factors, lipoproteins, and other lipids, as well
as several types of RNA.105,106,110,111 Platelet exosomal membrane pro-
teins also reflect their platelet source, including the constitutively
expressed glycoprotein GPIb, as well as GPVI, aIIbb3, CD40 ligand, and
P-selectin from activated platelets.105,106
It has been suggested that platelet activation in some vascular diseases
will elevate loading of cyto-adhesive, thrombogenic, and inflammatory
factors into platelet exosomal cargo to promote their delivery to endo-
thelial cells and macrophages at sites of vascular lesions. Augmented
delivery of platelet exosomal atherogenic cargo to lesional endothelial
cells and macrophages, may consequently accelerate development of
vascular plaques, clots, and atherosclerosis.107,108,112
3.8 Technical control experiments for
mechanistic studies
Given that current methods of purification are imperfect, the inclusion
of appropriate control experiments is crucial (Table 1). First and fore-
most, any biological effects observed using purified EVs should be absent
in ‘sham’ control samples depleted of EVs. Furthermore, when using EVs
isolated from tissue culture medium, inhibition of exosome release may
be used to confirm EV involvement in a process (e.g. Rab27a and
Extracellular vesicles in diagnostics and therapy of the ischaemic heart 25
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Rab27b silencing).113 Current chemical inhibitors inhibiting sphingomye-
linase (e.g. GW4869) are not specific to exosome release.57
3.9 Recommendations for mechanistic
studies
EVs and exosomes appear to mediate a regulated process of intercellular
communication, which could be capitalized on in order to obtain infor-
mation more easily and less invasively than from in vivo experiments.
However, for studies of exosomal communication, advanced cell models
are needed that can compare the use of single cell types with multiple
cell types in a 2D or 3D structure. Once identified, exosomal signalling
molecules could potentially be used as biomarkers that reflect the cellu-
lar state during cardiovascular disease.
Mechanistic experiments should include ‘sham’ EV-depleted control
groups. A dose-response curve should be performed to relate the mech-
anism of action to the EV concentration. Because of the hundreds of dif-
ferent bioactive molecular species in any EV preparation it is often
difficult to ascribe function to a specific EV component. At minimum, an
association between a protein/miRNA and EVs in support of any func-
tion ascribed to them, e.g. using immuno-EM, or co-purification on a den-
sity gradient should be performed. It is important to consider the
likelihood that a single miRNA or EV component mediates all of its
effects, as opposed to there being a network effect of multiple miRNAs,
and other mediators.83
4. EVs as biomarkers for the
ischaemic heart
Given their easily-accessible presence in bodily extracellular fluids, EVs
have been investigated as potential biomarkers for many diseases, and
their presence in blood and pericardial or lymphatic fluid lends promise
to their use in ischaemic heart disease. Proteins, lipids, coding and non-
coding RNAs, and even DNA specific to their cells of origin are incorpo-
rated into EVs and released into bio-fluids. They have therefore been
described as a form of ‘liquid biopsy’ of the cell of origin, and its patho-
physiological status, and are attractive sources of biomarkers for clinical
diagnostic applications in ischaemic heart disease.114 Their power
derives from the enrichment of potential protein markers which other-
wise constitute only a very small proportion (less than 0.01%) of the
total proteome of body fluids.115 Their sequestration within membranes
might also protect the cargo from degradation. Similarly, many miRNAs
detectable in serum and saliva are concentrated in exosomes,116 where
they are protected against RNases.117 The RNA content of EVs, espe-
cially the miRNA, has provoked great interest as diagnostic biomarkers
in exosomal RNA research.118 Technical issues related to analysis of EV
RNA and proteins contents are described in Section 2.2.8.
Several potential applications for novel biomarkers can be identified.
Blood-borne biomarkers of persistent myocardial ischaemia or vascular
injury without concomitant cell death are lacking. Subclinical or silent
myocardial ischaemia without infarction, different variants of angina and
especially microvascular angina86 would benefit from additional non-
invasive diagnostic options in addition to ECG.119 Furthermore, in popu-
lation studies, biomarkers of persistent low grade myocardial ischaemia
without cell death would help to determine the prevalence of such con-
ditions. Similarly, diagnosis of acute coronary syndrome (ACS) need to
be improved, especially at early time points after coronary occlusion,120
for microvascular angina and in the case of non-ST segment elevation
ACS.121 Given the wide range of cardiac cell types that are capable of
releasing EVs upon exposure towards stress, it is clear that circulating
EVs offer great potential for the identification of biomarkers to aid diag-
nosis. Indeed, circulating MV signature (characterized by e.g. CD66bþ/
CD62Eþ/CD142þ, or CD235aþ) in coronary and/or peripheral has
been shown to reflect the formation of coronary thrombotic occlusions
in STEMI-patients.122,123 Moreover, EVs of lymphatic origin have been
recently shown in mice as promising biomarkers for lymphatic dysfunc-
tion or inflammatory disease progression in atherosclerosis.124
4.1 EV number as biomarker
The number of EVs including exosomes seem to be associated with the
presence of cardiac ischaemia and correlates with the severity of cardiac
injury. The number of procoagulant EVs, particularly MVs, is elevated in
the peripheral blood of patients with ACS and chronic ischaemic heart
disease.3,5 The quantity of endothelium-derived MVs even allowed dis-
crimination between patients with stable angina, first time-, and recurring
myocardial infarction.125 Both systemic and intracoronary endothelial
and platelet MV correlated with the degree of thrombosis and ischaemic
area at risk.126,127 MV protein levels are associated with increased risk
for future vascular events and mortality in patients with clinically manifest
vascular disease.128 In atherosclerosis, increases in EVs of various cell ori-
gins have been demonstrated, predicting cardiovascular morbidity and
mortality.129 However, since reports on both pro- and anti-
atherosclerotic effects of different EV populations have been published
(see for review: Ref.130), their usefulness as diagnostics needs further
exploration. Given the caveats mentioned previously with regards the
accuracy of current methods of EV quantification, it is important to
establish rigorous guidelines for consistency, and to determine the accu-
racy and precision (coefficient of variation) of the methods used.
4.2 EV content as a source of biomarkers
Since EV content is altered by pathology, diagnostics based on the analy-
sis of exosomal content of body fluids may provide further benefit for
diagnosing ischaemic heart diseases. The concentration of certain
miRNAs in the blood, such as miR-208a, miR-133a, and miR-499 is ele-
vated after ACS.80,131 Circulating miRNA have therefore been proposed
as diagnostic biomarkers in cardiovascular diseases.118,119,132–134 Some
of these may be transported by EVs, especially under pathological condi-
tions80,116,135,136 or after coronary-artery by-pass graft surgery.137 MVs
containing miR-126 and miR-199a, but not freely circulating miRNA
expression, predict the occurrence of CV events in patients with stable
coronary artery disease.138 Assessing miRNAs carried specifically by
exosomes can even improve diagnostic sensitivity and precision: exoso-
mal miR-208a content correlated well with cTn-I levels after CABG sur-
gery, while the whole-blood miR-208a levels did not.137 Similar results
were recently reported in ACS patients, where sensitivity of exosomal
miR-208a measurement was superior to that of the serum, which even
showed a certain degree of prognostic value regarding 1-year survival
rate.139 Exosomal miR-192, miR-194, and miR-34a have been identified
as prognostic biomarkers predicting the development of heart failure
and pathological remodelling after myocardial infarction.140
The diagnostic value of EV protein content has been little studied. De
Hoog et al. found that the proteome of ExoQuickTM-precipitated EVs
from ACS patients differed from those from non-ACS patients: elevated
vesicular levels of polygenic immunoglobulin receptor, cystatin C, and
complement factor C5a was associated with ACS diagnosis.141 Zhang
26 J.P.G. Sluijter et al.
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..et al. showed that protein levels in EV sub-fractions are associated with
heart failure in dyspnea cohort.22
4.3 The effect of co-morbidities on EVs
It is well known that cardiovascular risk factors and co-morbidities (espe-
cially aging, gender, and metabolic diseases such as hyperlipidaemia and
diabetes), and their medications alter the phenotype of the normal and
pathological myocardium including its response to ischaemia/reperfusion
and cardioprotective or regenerative therapies (see for extensive
reviews).142–145 The presence of these confounding factors may inter-
fere with diagnostic opportunities by means of MVs, however, very little
is known in this field. Some recent reviews on the diagnosis of diabetes
and dyslipidaemia concluded that since EVs may be involved in these
pathologies, analysis of EVs might reveal additional biomarkers.146–148
For example, the quantity of MVs/microparticles is elevated in the blood
plasma of patients with metabolic syndrome,149,150 and elevated levels of
certain miRNAs derived from ExoQuick-precipitated EVs have been
shown to be associated with metabolic syndrome or diabetes,151 but the
practical relevance of these reports is yet to be assessed. Since the car-
diac transcriptome including miRNA expression profile has been shown
to be dramatically changed in the rat myocardium by hyperlipidemia,152
analysis of transcriptome including non-coding RNA content of EVs may
provide specific diagnostic markers of the heart affected by this and
other co-morbidities.153 In a study on over 1000 patients, EV-associated
cystatin C content was found to be significantly elevated (a marginal, 9%
difference), in metabolic syndrome patients with cardiovascular disease,
and a proteomics study on EVs derived from adipocytes of obese rats
revealed 200 proteins with differential expression.154 Moreover, it has
been shown that at similar plasma cholesterol levels, patients on statin
treatment had a significant lower number of circulating MVs carrying
markers of activated cells.155 These studies suggest that EVs have the
potential to evolve into useful biomarkers of various metabolic diseases
in the future, however, a substantial amount of research has to be done
before their clinical use might be realized.
4.4 Recommendations for study of EVs as
biomarkers
Since miRNAs are transferred by either protein complexes, HDL, or
EVs,134 and since protein contamination of isolated EVs is difficult to con-
trol, adequate isolation techniques are of the utmost importance if exo-
somal miRNAs or proteins are to be assessed as biomarkers. Other
recommendations relevant to plasma miRNA biomarker studies in gen-
eral apply equally to EV miRNA studies.156 It should be noted that
although detectable amounts of relatively clean EVs can be isolated, e.g.
with size exclusion chromatography,29 methods for the isolation of EVs
need to be improved to allow clinical utilization of EV-based diagnostics.
Current technical limitations for EV isolation do not allow definitive
guidelines for the use of EVs as biomarkers. Several factors that are lack-
ing include: the lack of standardized pre-analytical and isolation proce-
dures; lack of gold standard for processing, characterization and purity;
an unknown influence of comorbidities, co-medication and other con-
founding factors; lack of disease specificity; lack of tissue-specific markers
(Table 2). As with any biomarker study, pilot observations from small
cohorts should be validated in larger patient datasets, and the reproduci-
bility of isolation procedures, including markers of EVs and normal range
levels in the healthy population should be reported. Moreover, evidence
should be provided of the additional value of EVs over current gold-
standard biomarkers.
5. Therapeutic potential of EVs for
the ischaemic heart
EVs purified from defined cell types have been suggested as novel thera-
peutic options for various cardiac diseases including ischaemic heart dis-
ease, myocardial infarction, and heart failure, as well as for pathogen
vaccination, immune-modulatory and regenerative therapies and drug
delivery. However, the first clinical steps have been made using exo-
somes as an anti-tumour therapy: an effective way to destroy non-small
cell lung cancer (NSCLC) is to activate tumour-specific cytotoxic T cells
(CTL), and for this autologous dendritic cell (DC)-derived exosomes
(DEX) loaded with tumour antigens have been tested not only in phase
I157 but also in a phase II Trial (ClinicalTrials.gov Identifier:
NCT01159288). Although this did not induce detectable effector T cell
responses, a positive effect on natural killer (NK) cells could be observed
in some patients.158 This first exosome Phase I trial highlighted the feasi-
bility of large scale exosomes production and the safety of exosome
administration.159 Several other Phase I studies have been initiated,
exploring the use of EVs/exosomes as a therapy, including the effect of
MSC-derived exosomes on b-cell mass in Type 1 diabetes mellitus
(T1DM) Patients (ClinicalTrials.gov Identifier: NCT02138331).
Little is known about whether EVs derived from animals might be fea-
sible for human therapy. However, EV fractions derived from human
umbilical cord MSCs and administered to different healthy and diseased
animal species (including rats with myocardial infarction) were found to
be well tolerated.160 After further study, these results demonstrating a
lack of adverse immunological reactions may open the possibility of pro-
ducing therapeutic EVs from non-human sources. To develop the appli-
cation of exosome-based therapeutics, a clear understanding of
Table 2 Current technical limitations for clinical translation of EV biomarker
(1) Lack of standardized pre-analytical and isolation procedures.
(2) Currently no gold standard.
(3) Need to establish methods of purifying specific subpopulations of EVs originating from the heart, vasculature, or blood cells, no golden standard for process-
ing, characterization, and purity.
(4) Unknown influence of confounding factors of EV quality, including disease specificity and presence of comorbidities and their medications.
(5) Small yields of EV subpopulations obtained for content analysis: transcriptomics, lipidomics, and proteomics.
(6) Validation of novel biomarkers in large patient cohorts, including normal range levels in the healthy population.
(7) Determine additional value of EV markers over current golden standard clinical biomarkers, or its use as a combinatory marker.
Extracellular vesicles in diagnostics and therapy of the ischaemic heart 27
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
exosome pharmacokinetics in vivo is of utmost importance. Currently,
only limited information is available, but unmodified EVs derived from
tumours are rapidly cleared in liver and spleen by the reticuloendothelial
system and cells of the innate immune system.161 Interestingly, there
may be concerns about intravenous injection of high concentrations of
EVs since the authors observed rapid asphyxiation of mice when inject-
ing over 400mg.161 To date, most in vivo bio-distribution studies have
used small lipophilic fluorescent dyes to label EVs. Although useful for
first impressions, the reliability of these analyses might be impaired by
the free dye released from EVs.162 Bioluminescence imaging of a fusion
protein consisting of Gaussia luciferase and lactadherin has been used to
demonstrate that EVs quickly disappear from the blood circulation and
are mainly distributed to the liver after intravenous injection into mice,
with a half-life of approximately 2–4 min.163 It is likely that surface mole-
cules such as phospholipids and proteins are important for determining
the pharmacokinetics and cellular uptake of EVs.164 A further question
relates to the ideal route of EV administration. In this regard, a recent
study demonstrated that MSC-derived EVs were effective in pigs after
intramyocardial but not intracoronary delivery post reperfusion.165
5.1 Progenitor and stem cell-derived EVs
Stem cell therapy has been investigated as a potential approach to pre-
vent cardiac damage and stimulate cardiac repair in ischaemic heart dis-
ease.143 Recent developments in regenerative medicine that explore the
use of cell-free approaches, hence using the isolated paracrine effectors
from cells, focus on EVs that are release by cultured cells.2,81 The use of
these vesicles provide an alternative strategy for the paracrine effects of
cell transplantation and activation of the repair mechanisms of the resi-
dent myocardium that captures the complexity of the signalling required
to stimulate these regenerative processes.
The best studied population of cells for its paracrine effects in the heart
are the mesenchymal stromal cells (MSCs). Conditioned medium of
these cells reduced infarct size in both murine and porcine animal mod-
els,166,167 after which the exosome-containing fraction was demonstrated
to be the functional fraction, which decreased oxidative stress and acti-
vated the PI3K/Akt pathway in the myocardium.45,168 As indicated above,
several subclasses of EVs might be released by cells. A recent study
showed that MSCs produce at least three subtypes of EVs, isolated based
on their affinities for membrane lipid-binding ligands, and are likely to
have a different biogenesis pathway and possibly different functions.169,170
In addition to the cardioprotective effects of EVs, pro-angiogenic
effects have been observed,170 not only by MSCs but also by cardiac-
derived progenitor cells (CPCs), which are at least partly mediated via
extracellular matrix metalloproteinase inducer (EMMPRIN).85,86,171 In
the EVs of CPCs, several miRNA clusters are enriched and important for
their therapeutic effects.82,83 EVs derived from blood-outgrowth endo-
thelial cells91,172 and especially circulating CD34þ stem cells90 were also
shown to exert pro-angiogenic paracrine activity. EVs are now being
reported to have anti-inflammatory effects as well, e.g. endothelial cell-
derived EVs were found to suppress monocyte activation.173 EVs har-
vested from Treg cells have been found to exert an immune-suppressive
function by the suppression of monocyte activation,174 and EVs from
MSCs can suppress T-Lymphocyte proliferation.175,176
Mouse embryonic stem cells secrete exosomes which can also aug-
ment neovascularization, myocyte proliferation, and survival after MI.177
Importantly, they were shown to augment the survival, retention, and
proliferation of CPCs in ischaemic myocardium by delivery of miR-
294.177 Exosomes have also been identified as key mediators of regener-
ation induced by cardiosphere-derived cells (CDCs), which they
achieved partly by the transfer of miR-146a.81 Recently, CDC exosomes
isolated by filtration and precipitation were injected into the myocar-
dium of pigs following ischaemia and reperfusion, which reduced infarct
size and improved cardiac function 4 weeks later.165
Recent studies described the isolation of EVs from iPSCs, with healing
ability in in vivo model of myocardial ischaemia.178 Finally, plasma EVs
themselves have been shown to be able to protect the myocardium
from ischaemia and reperfusion injury179 and EVs have been shown to
be necessary for endogenous cardioprotective mechanisms such as
remote ischaemic conditioning.46
5.2 Hybrid nanomedicine to mimic EVs
A further approach to the use of EVs as therapeutic tools is to load them
with a range of molecules or pharmacological compounds from siRNA
to small molecules or proteins, serving as tool for empowering cell-
derived EVs and for targeted-drug delivery.180 For example, liposomes
with a phospholipid bilayer can carry a variety of proteins and nucleic
acids as well as pharmaceutically active substances to the injured
heart.181 Such exosome-mimetic structures can also include specific tar-
geting molecules that enhance their targeting. Currently, liposomal trans-
port of drug molecules are in clinical practice and under clinical
trial.182,183 Exosome-mimetic delivery systems offer the advantage of
being more controllable and scalable for clinical settings.184,185
Conversely, the advantage of using EVs in targeted drug delivery over
the existing synthetic delivery systems (such as liposomes) includes their
potentially increased circulation time, bio-distribution, decreased immu-
nogenicity and toxicity, loading of complex cargo, cellular interactions
and the different methods for therapeutic cargo loading (both post-
loading and pre-loading) and administration.
5.3 Important limitations to overcome in
the development of EV therapeutics
The use of EVs provides several advantages over the use of cells for ther-
apeutic application. These include the absence of tumourigenicity, con-
servation of activity between species, lower immunogenic potential, and
theoretically improved tissue-targeting potential. However, before EVs
can enter the clinic as medicinal products several important steps have
to be taken (Table 3)43:
(1) Therapeutic differences from independent cell preparations have been
observed among comparable EV fractions, which might be caused by
variability between donors or heterogeneity of EVs harvested.169 Since
cellular growth status varies between cell cultures, as it does for embry-
onic stem cells or MSCs,186 these differences might also be reflected in
their secreted EVs.
(2) Upon EV isolation and usage, contamination by co-purified and bound
molecules might affect functional assays.12
(3) Since isolated EVs might be heterogeneous by nature, only a propor-
tion of produced EVs might be responsible for observed therapeutic
effects.
(4) The EV pharmacokinetics are largely unknown and need detailed follow-
up in patients to understand their bio-distributions.
(5) The approach of using non-autologous EVs in the setting of cardiovascular
disease should be taken carefully, since EVs can potentially carry
pathogen-specific antigens.
(6) Currently, as it is unknown which EV fraction (content, membranes or
both) is responsible for the biological activity of EVs, the mechanism of
action should investigated.
(7) Prior to entering into clinical trials, industrial-scale, highly reproducible
methods of isolating GMP-quality EVs, as well as validation procedures are
required.
28 J.P.G. Sluijter et al.
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..6. Consensus statement on the
steps required to take EVs forward
to clinical applications as
biomarkers or therapeutics
Biomarkers: As indicated in Section 4.4., the current technical limitations
for EV isolation do not allow specific recommendations for the use of
EVs as biomarkers, though guidelines for biomarkers in general are appli-
cable. In the coming years, standardized pre-analytic and isolation proce-
dures need to be further defined and simplified, including the definition
of gold standards for processing, characterization, and identification of
EV purity (Table 4). By exploring these areas, the influence of confound-
ing factors, including co-morbidities, co-medication and whether identi-
fied EV markers are disease specific will be evaluated. The typically small
yields of isolated EVs will hamper a clear full EV characterization, but
technical developments that allow, for example, single cell sequencing
will lower input needs for these techniques. Most important is the valida-
tion of pilot observation from small cohorts in larger dataset of patients,
thereby improving the reproducibility of isolation procedures, and to
provide evidence of additional value of EVs over current golden standard
biomarkers. To strengthen the process of identification of EVs or EV-
components as biomarkers, experiments may also be designed to iden-
tify the tissue source of the biomarker, combined with the functional vali-
dation of the identified molecule (protein and/or RNA) in the target
tissues.
Therapy: The translation of EVs into clinical therapies will require cat-
egorization of EV-based therapeutics in compliance with existing regula-
tory frameworks. Since EVs will probably be considered as biological
medicinal products more specifically advanced therapy medicinal
products (ATMPs), new rules explicitly regulating EV-based therapies
are probably not needed. However, although existing European guid-
ance on biological active substances covers the manufacturing and clini-
cal evaluation of novel EV-based therapeutics, special guidelines
addressing EV-based therapeutics may be needed.43 The regulatory clas-
sification of most biological medicinal products, including ATMPs
depends on a pharmaceutically active substance that does not require a
molecular definition, but could mean the cells themselves in case of cellu-
lar therapeutics.187 Here, one needs to identify, quantify, and character-
ize the main effector that is causing the biologic effect and define the
mode or mechanism of action.
Similar to human cell-based products,188 preclinical safety testing
might be needed as well as a risk-analysis approach for the transition
from preclinical to clinical development, thereby taking into account the
heterogeneity among independent cell donors and different prepara-
tions, as well as the EV heterogeneity in obtained donor cell samples.
A test for biological activity should be included unless otherwise justified.
However, since many cell products are composed of a heterogeneous
mixture of cells, identification of the cellular component(s) responsible
for a proposed biological activity will be a major challenge. General clini-
cal requirements and developments have been recently reviewed for
cardiac cellular therapeutics.143
Based on the legislation for ATMPs including tissues, cells, a set of min-
imal criteria for the characterization of such products needs to be con-
sidered before use in clinical trials. One needs to define whether a
product is (i) of autologous, allogeneic or xenogeneic origin; (ii) exten-
sively or minimally manipulated in vitro; and (iii) immunologically active or
neutral, (iv) is the proliferative capacity of cells and tissue-like organiza-
tion, as well as defining (v) the dynamic interaction between these ele-
ments, (vi) the intended use.43,189
Table 4 Future perspectives: Developments required to take EVs forward to clinical applications as biomarkers or
therapeutics
– Improvement of flow cytometric methods and standardization of analytical procedures. (Until this is achieved, bead-based bulk detection of EVs may provide
a feasible flow cytometric detection approach irrespective of the instrument used).
– Development of novel high-resolution methodologies for EV isolation and visualizations.
– Understand mechanism of inter-cell or inter-organ communication.
– Potential source for cardiac tissue and disease specific biomarkers.
– Potential packages for cardiac specific therapies.
– Potential multi-targeting effects of EVs for the complex mechanisms of ischaemic heart disease.
– Potential advantage for EV therapeutic application over cells, including absence of tumourigenicity and cross species efficacy.
Table 3 Current limitations for cardiac therapeutic use of EVs
(1) Unestablished regulatory aspects.
(2) Scalable production and stability of EVs.
(3) Purification problem, including potential heterogeneity of EVs and presence of co-purified molecules.
(4) Lack for standardized quality control methods for EV production.
(5) Determine which proportion of EVs mediates therapeutic effects, including unknown mode of action, including potential retention issues.
(6) Unknown pharmacokinetics of EVs as a therapeutic.
(7) Unknown safety and toxicity, including immunogenicity.
(8) Difficulty for freedom to operate due to regulatory protection issues.
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In summary, to advance towards first-in-man-clinical trials approval of
the technical requirements and quality risk management is needed,
donor safety, recipient safety, and release criteria for EV-based therapeu-
tics should be defined and quality control should be in place, including
molecular and physical EV characterization, and in vitro potency assays.
Moreover, the identified recommendation criteria for the characteriza-
tion of isolated EV are critical for both their therapeutic use and for bio-
marker discovery.
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